Legend Biotech Corp
Research Legend Biotech Corp (LEGN) on Bullrun: market cap USD 3.31B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerLEGN
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 3.31B
- Financial periodQ2 2026
- RevenueUSD 387.50M
- Net incomeUSD 33.20M
- Free cash flow-USD 28.40M
- Gross margin64.5%
Valuation Snapshot
latest market cap is USD 3.31B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 1.03B | -USD 296.80M | -USD 128.80M | 60.3% | -1.62 | USD 901.90M | USD 413.70M | USD 1.00B |
| FY2024 | USD 627.30M | -USD 177.00M | -USD 158.10M | 62.6% | -0.96 | USD 286.70M | USD 350.60M | USD 1.04B |
| FY2023 | USD 285.10M | -USD 518.30M | -USD 416.00M | 49.4% | -2.94 | USD 1.28B | USD 328.67M | USD 1.25B |
| FY2022 | USD 117.01M | -USD 446.35M | -USD 223.56M | 44.1% | -2.8 | USD 786.03M | USD 284.53M | USD 744.31M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 3.31B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 4.01B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 5.98B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 10.97B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 8.36B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 7.19B | n/a | n/a | n/a |
About Legend Biotech Corp
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM).
ETFs that hold Legend Biotech Corp
Legend Biotech Corp is one of the ten largest holdings of one ETF that investors in Europe can buy:
| ETF | Weight | TER |
|---|---|---|
| Harbor Health Care UCITS ETF - Accumulating | 4.90% | 0.89% |
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Legend Biotech Corp's market cap?
Legend Biotech Corp's market capitalization is USD 3.31B.
What does Legend Biotech Corp do?
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM).